Breakthroughs can’t wait for people living with brain tumors and their loved ones.

NBTS’s DNA Damage Response Consortium brings together best-in-class researchers, including Ranjit Bindra, MD, PhD, at the Yale Cancer Center/Smilow Cancer Hospital, to expedite the process of translating research discoveries into the clinical setting.

NBTS funding drives the consortium’s work to cultivate a budding area of drug development targeting the DNA damage response networks in brain tumors. This research could transform the treatment landscape for many types of malignant brain tumors, both in children and adult patients.

Learn more: [ Ссылка ]

#NationalBrainTumorSociety #braintumorcommunity #braintumorresearch #braintumorawareness

свернуть